Rani Therapeutics
RANI
24 hedge funds and large institutions have $34.5M invested in Rani Therapeutics in 2022 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 6 increasing their positions, 7 reducing their positions, and 4 closing their positions.
70% more capital invested
Capital invested by funds: $20.3M → $34.5M (+$14.2M)
50% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 4
9% more funds holding
Funds holding: 22 → 24 (+2)
6.68% more ownership
Funds ownership: 6.3% → 12.97% (+6.7%)
14% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 7
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AI
Alphabet Inc
Mountain View,
California
|
+$11.9M |
| 2 |
USAA
United Services Automobile Association
San Antonio,
Texas
|
+$7.99M |
| 3 |
LM
Lasry Marc
|
+$1.04M |
| 4 |
BlackRock
New York
|
+$715K |
| 5 |
Millennium Management
New York
|
+$540K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Squarepoint
New York
|
-$818K |
| 2 |
CCM
CAAS Capital Management
New York
|
-$228K |
| 3 |
CH
Canton Hathaway
Providence,
Rhode Island
|
-$82K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$35K |
| 5 |
JP Morgan Chase
New York
|
-$30.8K |
RANI Hedge Fund Activity: Q1 2022 in Review
24 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Rani Therapeutics (RANI) for Q1 2022, worth a combined $34.5M — up 70% from $20.3M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new RANI positions and 4 closed out — a net gain of 2 holders — while 6 added to existing stakes and 7 trimmed.
The largest buyer was Alphabet Inc, opening a new position worth an estimated $11.9M. The largest seller was Squarepoint, exiting entirely with an estimated $818K sold.
- 24 institutional investors held Rani Therapeutics (RANI) as of Q1 2022, up from 22 in Q4 2021.
- Funds reported $34.5M of Rani Therapeutics stock for Q1 2022, up 70% quarter-over-quarter.
- 6 funds opened new Rani Therapeutics positions in Q1 2022 and 4 closed out, a net change of +2 holders.
- The largest Rani Therapeutics buyer in Q1 2022 was Alphabet Inc, an estimated $11.9M added.
- The largest Rani Therapeutics seller in Q1 2022 was Squarepoint, an estimated $818K sold.
Based on aggregated 13F filings for Q1 2022.